Radical Numerics raises $50M in Seed

Radical Numerics Inc., an artificial intelligence research lab, has secured a $50 million seed funding round led by Emergence Capital. The financing is intended to boost the company’s efforts to develop what it describes as general biological intelligence, focusing on advanced AI models capable of integrating various biological data sources, such as DNA and proteins, into a cohesive system. This initiative seeks to transform approaches in fields like cancer diagnostics, drug target identification, and biosecurity.

The leadership team comprises experienced AI experts, including Eric Nguyen as CEO, along with Michael Poli, Stefano Massaroli, and Armin Thomas, all having previously contributed to model design at Liquid AI Inc. Radical Numerics' scientific advisory board features prominent figures such as Microsoft's Eric Horvitz and geneticist George Church. The start-up's prior developments, notably the Evo model for DNA reading and writing, have been recognized in leading scientific journals, underpinning its ambitious new venture.

Radical Numerics aims to integrate its AI capabilities into healthcare and biosecurity applications. Through its Omnii genomic language model, the company is achieving breakthroughs such as identifying genetic variants associated with diseases like Alzheimer's and detecting AI-generated pathogens. CEO Eric Nguyen emphasizes the dual purpose of its technology: advancing biological design for health enhancements while safeguarding against potential bio-risks. Nguyen notes that as AI assists in curing diseases, it simultaneously lowers barriers to harmful biological design, a duality that necessitates caution.

Emergence Capital's involvement, alongside investors like Obvious Ventures and Factory, underscores the broader interest in leveraging AI's potential in biotechnology. The market continues to witness significant capital allocation towards AI-driven biological research, a trend expected to influence competitive dynamics in the biotech sector. Radical Numerics’ focus on multimodal AI models places it among a handful of cutting-edge firms seeking to harness AI for deep biological insights.

As Radical Numerics progresses, it will need to navigate the complex regulatory landscape surrounding AI in biological applications. Ensuring compliance and addressing ethical considerations will be critical as it works on potentially high-stakes applications in healthcare and defense. The industry will be watching closely to see how Radical Numerics' technology evolves and what impact it may have on both innovation and regulation in biological intelligence.